Similar articles

• Unwarranted use of intravenous aminoglycosides at UK paediatric cystic fibrosis centres.

  Ditchfield N, Carroll WD, Gilchrist FJ. Ditchfield N, et al. J Cyst Fibros. 2019 Nov;18(6):e58-e59. doi: 10.1016/j.jcf.2019.09.004. Epub 2019 Sep 12. J Cyst Fibros. 2019. PMID: 31522925 No abstract available.
• Risk factors for aminoglycoside ototoxicity in adult cystic fibrosis patients.

  O'Donnell EP, Scarsi KK, Scheetz MH, Postelnick MJ, Cullina J, Jain M. O'Donnell EP, et al. Int J Antimicrob Agents. 2010 Jul;36(1):94-5. doi: 10.1016/j.ijantimicag.2010.02.018. Epub 2010 Apr 10. Int J Antimicrob Agents. 2010. PMID: 20382508 No abstract available.
• Ototoxicity of aminoglucoside antibiotics in long-term treatment for cystic fibrosis.

  Crifo S, Antonelli M, Gagliardi M, Lucarelli N, Marcolini P. Crifo S, et al. Int J Pediatr Otorhinolaryngol. 1980 Sep;2(3):251-3. doi: 10.1016/0165-5876(80)90050-6. Int J Pediatr Otorhinolaryngol. 1980. PMID: 6821312 No abstract available.
• [Pathomorphological aspects of the action of aminoglycoside antibiotics on the acoustic analyzer].

  Zhuravskiĭ SG, Tomson VV, Tsvyleva ID, Ivanov AG. Zhuravskiĭ SG, et al. Vestn Otorinolaringol. 2003;(2):55-60. Vestn Otorinolaringol. 2003. PMID: 12958868 Review. Russian. No abstract available.
• Extended-interval once-daily dosing of aminoglycosides in adult and pediatric patients with cystic fibrosis.

  Prescott WA Jr, Nagel JL. Prescott WA Jr, et al. Pharmacotherapy. 2010 Jan;30(1):95-108. doi: 10.1592/phco.30.1.95. Pharmacotherapy. 2010. PMID: 20030477 Review.